Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 2:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1873–1896 of 2,513 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: RAPID Clear all

Conditions: Prostate Cancer
Interventions: rhPSMA-7.3 (18F); Drug
Lead sponsor: MidLantic Urology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Bala-Cynwyd, Pennsylvania

Conditions: Hiv, HIV Infections
Interventions: 60-Minutes-For-Health, Time-and-Attention Control Session; Behavioral · Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 85 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: San Diego, California

Conditions: Type 1 Diabetes Mellitus
Interventions: Omnipod Insulin Management System; Device
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 1 Year to 8 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Nonsmall Cell Lung Cancer Stage III, Unresectable Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II
Interventions: Durvalumab, the EORTC Core Quality of Life Questionnaire (EORTC QLQ-C30), COPD Assessment Test (CAT), Modified Medical Research Council (mMRC) dyspnea scale; Drug · Other · Diagnostic Test
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Charlotte, North Carolina • Winston-Salem, North Carolina

Conditions: Pulmonary Disease, Chronic Obstructive, Emphysema
Interventions: Silicone Stent Airway Implant; Device
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Hepatic Impairment
Interventions: Lemborexant; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Cystic Fibrosis-related Diabetes
Interventions: Insulin, Continuous glucose monitor (CGM); Drug · Device
Lead sponsor: Jagdeesh Ullal; Other
Eligibility: 18 Years to 80 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hypernatremia
Interventions: Intravenous Dextrose 5% solution; Drug
Lead sponsor: Columbia University; Other
Eligibility: 21 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Pulmonary Arterial Hypertension
Interventions: Parenteral Treprostinil, Oral Treprostinil; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 28
States / cities: Phoenix, Arizona • Fresno, California • Los Angeles, California + 23 more

Conditions: Acute Myeloid Leukemia
Interventions: MLN9708, Cytarabine, Daunorubicin; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 60 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Brain Metastases
Interventions: 18F-Fluciclovine (Axumin) PET/CT; Diagnostic Test
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 99 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: COVID-19 Testing Behaviors
Interventions: COVID-19 rapid test-to-treat, Standard COVID19 education control arm; Behavioral
Lead sponsor: University of Missouri, Kansas City; Other
Eligibility: 18 Years to 120 Years
Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Pharmacokinetics and Pharmacodynamics
Interventions: Fentanyl, Fentanyl Citrate; Drug
Lead sponsor: INSYS Therapeutics Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
Interventions: Health Coaching, Prolonged Overnight Fasting (POF), Mediterranean Diet, Supportive Materials; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Pulmonary Disease, Chronic Obstructive, Respiratory Insufficiency
Interventions: Vapotherm High Flow Therapy, Non-invasive positive pressure ventilation; Device
Lead sponsor: Vapotherm, Inc.; Industry
Eligibility: 50 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Small Bowel Bacterial Overgrowth, Gastrointestinal Diseases, Stomach Diseases, Digestive System Diseases
Interventions: Xifaxan, SmartPill, Lactulose hydrogen breath test (H_2BT); Drug · Device · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: ROHHAD, Rapid-Onset Obesity With Hypothalamic Dysfunction, Hypoventilation & Autonomic Dysregulation
Interventions: ROHHAD; Genetic
Lead sponsor: Ilya Khaytin; Other
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2039
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Schizophrenia
Interventions: 10 mg CVL-231 as IR formulation, 30 mg CVL-231 as slow-release MR formulation, 30 mg CVL-231 as medium release MR formulation, 30 mg CVL-231 as fast release MR formulation, 30 mg CVL-231 Target Release, Fasted, 30 mg CVL-231 Target Release, Fed; Drug
Lead sponsor: Cerevel Therapeutics, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Stroke Code, Large Vessel Occlusion, Acute Ischemic Stroke
Interventions: Point of Care Rapid Assay; Device
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 0 Years to 21 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Health Behavior
Interventions: Supported Employment; Behavioral
Lead sponsor: University of Oregon; Other
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Eugene, Oregon

Conditions: Hepatocellular Carcinoma
Interventions: TheraSphere Y-90 glass microsphere therapy, Durvalumab (Imfinzi) immunotherapy, Tremelimumab immunotherapy; Device · Drug
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 12
States / cities: San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 7 more

Conditions: Oral Mucositis, Nausea, Vomiting, Diarrhea
Interventions: ProThelial; Device
Lead sponsor: Ashley Downs Bioscience; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Foster, Rhode Island

Conditions: Fibromyalgia, Fibromyalgia Syndrome
Interventions: Transdermal Magnesium Chloride; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Infection
Interventions: Reusable respirator fit test and competency evaluation, Control fit test evaluation; Other
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 3
States / cities: Atlanta, Georgia • Detroit, Michigan • Houston, Texas

Search by objective public record fields.

Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management

Instacare - Rapid ART Initiation Among Persons With HIV and Out of Care

Fast Track CSII Using a Novel Device in Young Children With Newly Diagnosed T1DM

Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer

Evaluating the Clinical Effectiveness of 3D Printing for a Patient-specific Silicone Stent Airway Implant

Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects

Comparison of Meal-Time Dosing of Insulin in Cystic Fibrosis Related Diabetes

Rapid Rehydration for Severe Hypernatremia

A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension

MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age

Feasibility of 18F-Fluciclovine PET/CT to Identify Brain Metastasis

COVID-19 Rapid Test-to-Treat With African American Churches (Faithful Response II)

Fentanyl Sublingual Spray and Fentanyl Citrate Intravenous (IV) in Opioid Naive Subjects

FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease

High Flow Therapy (HFT) to Treat Respiratory Insufficiency in Chronic Obstructive Pulmonary Disease (COPD)

Transit Time and Bacterial Overgrowth Using SmartPill Capsule

International Rapid-onset Obesity With Hypothalamic Dysfunction, Hypoventilation & Autonomic Dysregulation (ROHHAD) Registry

Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants

Evaluation of a Point-of-care Lateral Flow Assay in Glial Fibrillary Acidic Protein (GFAP) and D-dimer in Diagnosis of Large Vessel Occlusion Acute Ischemic Stroke in a Pediatric Hospital

Supported Employment COVID-19 Rapid Testing for PWID

TheraSphere With Durvalumab and Tremelimumab for HCC

ZeroTolerance Mucositis: Managing Oral and Alimentary Mucositis With High Potency Sucralfate - ProThelial

Effect of Transdermal Magnesium Chloride on Quality of Life in Patients With Fibromyalgia

Just-in-time Elastomeric Training and Fit Testing (JET FIT)